Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy

Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy

US Patent 11717548 · Granted Aug 8, 2023

Estimated economic value: $35,266,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

RNA cleavage-induced transcript stabilizer and uses thereof2025
Uses of amphiphiles in immune cell therapy and compositions therefor2025
Fusion polypeptides comprising interleukin 12 and a metal-hydroxide binding poly2025
Fusion polypeptides comprising interleukin 12 and a metal-hydroxide binding poly2025
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof2025
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof2025
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using am2025
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using am2025
Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodula2025
Delivery of biomolecules to immune cells2025
Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy2025
Synthetic oncolytic LNP-replicon RNA and uses for cancer immunotherapy2025